Sinclair Dunlop - Jun 1, 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for A. Sinclair Dunlop
Stock symbol
APLS
Transactions as of
Jun 1, 2021
Transactions value $
$0
Form type
4
Date filed
6/2/2021, 04:23 PM
Previous filing
May 20, 2021
Next filing
Sep 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Other $0 -31.9K -100% $0.00* 0 Jun 1, 2021 See Footnote F1, F2
transaction APLS Common Stock Other $0 +13.1K +21.85% $0.00 73.1K Jun 1, 2021 Direct F1
transaction APLS Common Stock Other $0 +2.68K +0.89% $0.00 303K Jun 1, 2021 See Footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Distributions from MASA Life Science Ventures, LP ("MASA"), of which the reporting person is a managing partner. Of the 31,855 shares distributed by MASA, 13,108 were distributed to the reporting person and 2,682 were distributed to Epidarex Capital I, LP ("Epidarex").
F2 The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.
F3 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.